InMed Pharmaceuticals (NASDAQ: INM) is uniquely positioned to leverage the growing worldwide awareness of the potential of cannabinoids and the rising demand for rare cannabinoids. The company has begun this year on a high, following the 2021 acquisition of BayMedica and the launch of cannabicitran (“CBT”) sales. “With the launch of business-to-business sales of CBT in the health and wellness sector, InMed has further expanded its portfolio and its presence in the growing rare cannabinoid market,” reports a recent article. “CBT is the first of several new products InMed is planning to launch in the first half of 2022 in response to growing demand. ‘By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large-scale supplier of high-quality rare cannabinoids in these sectors,’ stated Shane Johnson, SVP and general manager of InMed’s subsidiary and recent acquisition BayMedica… For 2022, InMed expects to build on the successes achieved in 2021, especially the acquisition and integration of BayMedica, to secure consistent revenue growth and further advance its pharmaceutical drug development programs, transitioning to become a leading B2B supplier of rare cannabinoids in the consumer health and wellness market.”
To view the full article, visit https://ibn.fm/OMkwe
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
